IL6 and B-cell non-Hodgkin lymphoma: For B-cell non-Hodgkin lymphoma, the first line drugs rituximab and bendamustine (RB) increased serum IL-6 more than rituximab and CPA, DOX, vincristine, and prednisone (R-CHOP), and the levels of IL-6 correlated with increased fatigue three months after the end of chemotherapy [107].